RxSight enters the second half of the year as a one-product cataract franchise whose headline print no longer describes the operating company. The June quarter held reported revenue roughly flat only because a brand-new Alcon collaboration booked license income against a shrinking Light Adjustable Lens franchise. Product sales contracted as competitive trialing and softer patient sentiment hit the premium channel, and the new chief executive withdrew the full-year sales outlook to give a commercial reset room to breathe. The equity debate is whether that reset, plus Alcon's optional milestone stack, restores growth before the installed base stops compounding.
The Light Adjustable Lens remains the only intraocular implant that surgeons can reshape after cataract surgery with an office ultraviolet treatment. That clinical distinction did not prevent LAL unit volume from falling to 24917 implants. Twelve Light Delivery Devices went out the door, a trickle against an installed base that now sits at 1166 systems. Mid-tier users are flattening or shrinking even as heavy adopters keep expanding, which is why the new commercial plan is about depth inside existing practices rather than more boxes in new ones.
Cash and short-term investments still exceeded $200 million before the Alcon upfront arrived after quarter-end. That liquidity funds the reset, but it also explains why the equity now trades close to net cash: the market is assigning little residual value to a high-margin franchise that is shrinking. The question for the next several quarters is whether utilization inside the existing installed base turns back up before Alcon's refund window and optional feasibility decision define how much of the collaboration is real.